Literature DB >> 26676632

[FLS - three letters alter secondary fracture prevention].

N Suhm1,2, C Meier3, M Kraenzlin3, E Kungler4, B Savic4, S Mueller4, M Jakob4, D Rikli4.   

Abstract

The increasing importance of preventive measures in the field of orthopedics and trauma surgery becomes apparent because of the demographic changes and the high risk for secondary fractures following osteoporotic fractures. Within the fracture treatment chain, orthopedics and trauma surgery are in the "pole position" to initiate these measures in geriatric patients. In the past orthopedists and trauma surgeons have constantly accused of neglecting secondary fracture prevention in fragility fracture patients. There are several reasons that speak in favor of us undertaking a role in secondary fracture prevention: osteoporosis medication is highly effective in fracture prevention when correctly indicated, the positive effects of osteoporosis therapy on fracture healing and legal issues. Arguments that have been used to justify neglect of secondary fracture prevention are undesired side effects related to osteoporosis medications, such as atypical femoral fractures and osteonecrosis of the jaws, interference of some specific drugs with fracture healing and the working conditions in emergency departments. These run contrary to the consideration of chronic diseases such as osteoporosis, secondary osteoporosis and the underlying disease could be overlooked and the increasing complexity of medicinal osteoporosis therapy. In the first part of the article these arguments are weighed against each other. In the second part the concept of a fracture liaison service (FLS) is discussed. The FLS framework now allows an active role to be taken with respect to secondary fracture prevention despite the busy daily routine schedule. Implementation of an FLS is facilitated by dedicated instruction protocols and programs. Self-financing of an FLS is currently possible only in some specific healthcare systems. In healthcare systems in German-speaking areas a cross-financing must be available and the value of an FLS indirectly presented. Apart from the financial aspects, implementation of a FLS is also worthwhile because it can be looked on as the future driving force of innovation.

Entities:  

Keywords:  Fracture liaison service; Fragility fractures; Geriatric fracture centers; Prevention; Secondary fracture prevention

Mesh:

Year:  2016        PMID: 26676632     DOI: 10.1007/s00113-015-0122-8

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  9 in total

Review 1.  Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis.

Authors:  K Ganda; M Puech; J S Chen; R Speerin; J Bleasel; J R Center; J A Eisman; L March; M J Seibel
Journal:  Osteoporos Int       Date:  2012-07-25       Impact factor: 4.507

2.  Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women.

Authors:  Peter Peichl; Lukas A Holzer; Richard Maier; Gerold Holzer
Journal:  J Bone Joint Surg Am       Date:  2011-09-07       Impact factor: 5.284

3.  Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper.

Authors:  J Goldhahn; J-M Féron; J Kanis; S Papapoulos; J-Y Reginster; R Rizzoli; W Dere; B Mitlak; Y Tsouderos; S Boonen
Journal:  Calcif Tissue Int       Date:  2012-03-28       Impact factor: 4.333

4.  Fracture prevention in Kaiser Permanente Southern California.

Authors:  R Dell
Journal:  Osteoporos Int       Date:  2011-08-17       Impact factor: 4.507

5.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

6.  Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.

Authors:  Silvano Adami; Cesar Libanati; Steven Boonen; Steven R Cummings; Pei-Ran Ho; Andrea Wang; Ethel Siris; Joseph Lane; Jonathan D Adachi; Mohit Bhandari; Luiz de Gregorio; Nigel Gilchrist; George Lyritis; Gerd Möller; Santiago Palacios; Karel Pavelka; Resch Heinrich; Christian Roux; Daniel Uebelhart
Journal:  J Bone Joint Surg Am       Date:  2012-12-05       Impact factor: 5.284

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

8.  Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

9.  Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials.

Authors:  Deting Xue; Fangcai Li; Gang Chen; Shigui Yan; Zhijun Pan
Journal:  J Orthop Surg Res       Date:  2014-06-05       Impact factor: 2.359

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.